Skip to content

Study on the predictive efficacy of blood urine metabolic markers for osteoporotic fractures

Study on the predictive efficacy of blood urine metabolic markers for osteoporotic fractures

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600118897
Enrollment
Unknown
Registered
2026-02-12
Start date
2026-03-01
Completion date
Unknown
Last updated
2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoportic fracture

Interventions

Control group:None
Osteoportic fracture group:None

Sponsors

Shanghai Yangpu District Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1.Patients diagnosed with osteoporotic fractures within 3 months through imaging methods (X-ray or CT); 2.The fracture site exhibits typical characteristics of osteoporotic fractures (such as in the vertebrae, hip, distal radius, etc.); 3.The diagnosis criteria for osteoporosis in accordance with the World Health Organization (WHO) or relevant guidelines (typically: determined by dual-energy X-ray absorptiometry, with the T-value of bone density in the lumbar spine or hip = -2.5 SD). 4.Aged between 50 and 85 years old; 5.Voluntarily participate in this study and sign the informed consent form;

Exclusion criteria

Exclusion criteria: 1.Pathological fractures caused by severe trauma, metastasis of malignant tumors to the bones, or other clearly non-osteoporosis-related reasons (such as Paget's disease); 2.Suffering from other diseases that severely affect bone metabolism (such as hyperparathyroidism, Cushing's syndrome, active rheumatoid arthritis, etc.). 3.Taking drugs that affect bone metabolism for a long time (such as glucocorticoids, antiepileptic drugs, aromatase inhibitors, etc.); 4.Combined with severe dysfunction of the heart, liver and kidneys; 5.Having acute or chronic infections, autoimmune diseases, or other systemic inflammatory conditions;

Design outcomes

Primary

MeasureTime frame
Metabolic marker levels;

Secondary

MeasureTime frame
General information;

Countries

China

Contacts

Public ContactLige Song

Shanghai Yangpu District Central Hospital

6songlige@tongji.edu.cn+86 21 6569 0520

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 19, 2026